These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 23546174)
1. Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo. Zhang LL; Zhang J; Shen L; Xu XM; Yu HG Mol Med Rep; 2013 May; 7(5):1387-90. PubMed ID: 23546174 [TBL] [Abstract][Full Text] [Related]
2. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223 [TBL] [Abstract][Full Text] [Related]
3. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways. Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028 [TBL] [Abstract][Full Text] [Related]
4. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691 [TBL] [Abstract][Full Text] [Related]
5. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893 [TBL] [Abstract][Full Text] [Related]
6. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer. Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123 [TBL] [Abstract][Full Text] [Related]
7. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Kim MJ; Nam HJ; Kim HP; Han SW; Im SA; Kim TY; Oh DY; Bang YJ Cancer Lett; 2013 Jul; 335(1):145-52. PubMed ID: 23402820 [TBL] [Abstract][Full Text] [Related]
8. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Kim CW; Lu JN; Go SI; Jung JH; Yi SM; Jeong JH; Hah YS; Han MS; Park JW; Lee WS; Min YJ Int J Oncol; 2013 Nov; 43(5):1495-502. PubMed ID: 23970333 [TBL] [Abstract][Full Text] [Related]
9. Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells. Xu W; Chen GS; Shao Y; Li XL; Xu HC; Zhang H; Zhu GQ; Zhou YC; He XP; Sun WH Cancer Lett; 2013 May; 332(1):11-8. PubMed ID: 23376640 [TBL] [Abstract][Full Text] [Related]
10. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lin Y; Wang Z; Liu L; Chen L Lung Cancer; 2011 Mar; 71(3):291-7. PubMed ID: 20599289 [TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380 [TBL] [Abstract][Full Text] [Related]
12. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin. Hu W; Jin P; Liu W Cell Physiol Biochem; 2016; 38(3):1199-208. PubMed ID: 26982182 [TBL] [Abstract][Full Text] [Related]
13. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694 [TBL] [Abstract][Full Text] [Related]
14. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873 [TBL] [Abstract][Full Text] [Related]
15. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456 [TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistantgastric cancer cells to cisplatin. Mao Z; Bian G; Sheng W; He S; Yang J; Dong X Oncol Rep; 2013 Nov; 30(5):2288-96. PubMed ID: 23982423 [TBL] [Abstract][Full Text] [Related]
17. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814 [TBL] [Abstract][Full Text] [Related]
18. Ginkgolic acid (GA) suppresses gastric cancer growth by inducing apoptosis and suppressing STAT3/JAK2 signaling regulated by ROS. Liang JR; Yang H Biomed Pharmacother; 2020 May; 125():109585. PubMed ID: 32106377 [TBL] [Abstract][Full Text] [Related]
19. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway. Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965 [TBL] [Abstract][Full Text] [Related]
20. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway. Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]